News Articles | Pfizer Singapore

Biopharma Leaders Unite To Stand With Science

Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-19

Alibaba Cloud, Fintech Academy and Pfizer Partner to Accelerate Healthcare Innovations

LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer

RECENT PRESS RELEASES

18/09/2020 - Pfizer to Present Latest Scientific Advancements from Its Industry- Leading Portfolio at the ESMO Virtual Congress 2020

18/09/2020 - BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine

15/09/2020 - Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

14/09/2020 - Pfizer Hosts Virtual Investor Day

12/09/2020 - Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial

11/09/2020 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

10/09/2020 - Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 2020

09/09/2020 - Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-19

09/09/2020 - Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

08/09/2020 - Biopharma Leaders Unite To Stand With Science

03/09/2020 - Pfizer Invites Public to Register for Webcast of Virtual Investor Day on September 14 and 15, 2020

21/08/2020 - Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19

07/08/2020 - Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19

06/08/2020 - Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020

05/08/2020 - LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer